Amgen Presents New Tarlatamab Data In Small Cell Lung Cancer

Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC Late-Breaking Data Presented at ESMO and Published in the New England Journal of Medicine...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials